260 related articles for article (PubMed ID: 22156546)
1. Reduced phosphocholine and hyperpolarized lactate provide magnetic resonance biomarkers of PI3K/Akt/mTOR inhibition in glioblastoma.
Venkatesh HS; Chaumeil MM; Ward CS; Haas-Kogan DA; James CD; Ronen SM
Neuro Oncol; 2012 Mar; 14(3):315-25. PubMed ID: 22156546
[TBL] [Abstract][Full Text] [Related]
2. Noninvasive detection of target modulation following phosphatidylinositol 3-kinase inhibition using hyperpolarized 13C magnetic resonance spectroscopy.
Ward CS; Venkatesh HS; Chaumeil MM; Brandes AH; Vancriekinge M; Dafni H; Sukumar S; Nelson SJ; Vigneron DB; Kurhanewicz J; James CD; Haas-Kogan DA; Ronen SM
Cancer Res; 2010 Feb; 70(4):1296-305. PubMed ID: 20145128
[TBL] [Abstract][Full Text] [Related]
3. Metabolic consequences of treatment with AKT inhibitor perifosine in breast cancer cells.
Su JS; Woods SM; Ronen SM
NMR Biomed; 2012 Feb; 25(2):379-88. PubMed ID: 22253088
[TBL] [Abstract][Full Text] [Related]
4. Dual inhibition of PI3K and mTOR mitigates compensatory AKT activation and improves tamoxifen response in breast cancer.
Chen X; Zhao M; Hao M; Sun X; Wang J; Mao Y; Zu L; Liu J; Shen Y; Wang J; Shen K
Mol Cancer Res; 2013 Oct; 11(10):1269-78. PubMed ID: 23814023
[TBL] [Abstract][Full Text] [Related]
5. Multipoint targeting of the PI3K/mTOR pathway in mesothelioma.
Zhou S; Liu L; Li H; Eilers G; Kuang Y; Shi S; Yan Z; Li X; Corson JM; Meng F; Zhou H; Sheng Q; Fletcher JA; Ou WB
Br J Cancer; 2014 May; 110(10):2479-88. PubMed ID: 24762959
[TBL] [Abstract][Full Text] [Related]
6. Akt1 activation can augment hypoxia-inducible factor-1alpha expression by increasing protein translation through a mammalian target of rapamycin-independent pathway.
Pore N; Jiang Z; Shu HK; Bernhard E; Kao GD; Maity A
Mol Cancer Res; 2006 Jul; 4(7):471-9. PubMed ID: 16849522
[TBL] [Abstract][Full Text] [Related]
7. LY294002 and Rapamycin promote coxsackievirus-induced cytopathic effect and apoptosis via inhibition of PI3K/AKT/mTOR signaling pathway.
Chen Z; Yang L; Liu Y; Tang A; Li X; Zhang J; Yang Z
Mol Cell Biochem; 2014 Jan; 385(1-2):169-77. PubMed ID: 24072614
[TBL] [Abstract][Full Text] [Related]
8. Probing the PI3K/Akt/mTor pathway using
Phyu SM; Tseng CC; Fleming IN; Smith TA
Sci Rep; 2016 Nov; 6():36544. PubMed ID: 27811956
[TBL] [Abstract][Full Text] [Related]
9. Lactate and choline metabolites detected in vitro by nuclear magnetic resonance spectroscopy are potential metabolic biomarkers for PI3K inhibition in pediatric glioblastoma.
Al-Saffar NM; Marshall LV; Jackson LE; Balarajah G; Eykyn TR; Agliano A; Clarke PA; Jones C; Workman P; Pearson AD; Leach MO
PLoS One; 2014; 9(8):e103835. PubMed ID: 25084455
[TBL] [Abstract][Full Text] [Related]
10. MR Studies of Glioblastoma Models Treated with Dual PI3K/mTOR Inhibitor and Temozolomide:Metabolic Changes Are Associated with Enhanced Survival.
Radoul M; Chaumeil MM; Eriksson P; Wang AS; Phillips JJ; Ronen SM
Mol Cancer Ther; 2016 May; 15(5):1113-22. PubMed ID: 26883274
[TBL] [Abstract][Full Text] [Related]
11. Differential effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway in acute lymphoblastic leukemia.
Badura S; Tesanovic T; Pfeifer H; Wystub S; Nijmeijer BA; Liebermann M; Falkenburg JH; Ruthardt M; Ottmann OG
PLoS One; 2013; 8(11):e80070. PubMed ID: 24244612
[TBL] [Abstract][Full Text] [Related]
12. Dual blocking of mTor and PI3K elicits a prodifferentiation effect on glioblastoma stem-like cells.
Sunayama J; Sato A; Matsuda K; Tachibana K; Suzuki K; Narita Y; Shibui S; Sakurada K; Kayama T; Tomiyama A; Kitanaka C
Neuro Oncol; 2010 Dec; 12(12):1205-19. PubMed ID: 20861085
[TBL] [Abstract][Full Text] [Related]
13. Longitudinal inhibition of PI3K/Akt/mTOR signaling by LY294002 and rapamycin induces growth arrest of adult T-cell leukemia cells.
Ikezoe T; Nishioka C; Bandobashi K; Yang Y; Kuwayama Y; Adachi Y; Takeuchi T; Koeffler HP; Taguchi H
Leuk Res; 2007 May; 31(5):673-82. PubMed ID: 17007924
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy.
Tsurutani J; West KA; Sayyah J; Gills JJ; Dennis PA
Cancer Res; 2005 Sep; 65(18):8423-32. PubMed ID: 16166321
[TBL] [Abstract][Full Text] [Related]
15. Involvement of mTORC1 and mTORC2 in regulation of glioblastoma multiforme growth and motility.
Gulati N; Karsy M; Albert L; Murali R; Jhanwar-Uniyal M
Int J Oncol; 2009 Oct; 35(4):731-40. PubMed ID: 19724909
[TBL] [Abstract][Full Text] [Related]
16. Dual targeting of AKT and mammalian target of rapamycin: a potential therapeutic approach for malignant peripheral nerve sheath tumor.
Zou CY; Smith KD; Zhu QS; Liu J; McCutcheon IE; Slopis JM; Meric-Bernstam F; Peng Z; Bornmann WG; Mills GB; Lazar AJ; Pollock RE; Lev D
Mol Cancer Ther; 2009 May; 8(5):1157-68. PubMed ID: 19417153
[TBL] [Abstract][Full Text] [Related]
17. G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cells.
Gao N; Flynn DC; Zhang Z; Zhong XS; Walker V; Liu KJ; Shi X; Jiang BH
Am J Physiol Cell Physiol; 2004 Aug; 287(2):C281-91. PubMed ID: 15028555
[TBL] [Abstract][Full Text] [Related]
18. PKB/Akt mediates radiosensitization by the signaling inhibitor LY294002 in human malignant gliomas.
Nakamura JL; Karlsson A; Arvold ND; Gottschalk AR; Pieper RO; Stokoe D; Haas-Kogan DA
J Neurooncol; 2005 Feb; 71(3):215-22. PubMed ID: 15735908
[TBL] [Abstract][Full Text] [Related]
19. Dual inhibition of the PI3K/AKT/mTOR pathway suppresses the growth of leiomyosarcomas but leads to ERK activation through mTORC2: biological and clinical implications.
Fourneaux B; Chaire V; Lucchesi C; Karanian M; Pineau R; Laroche-Clary A; Italiano A
Oncotarget; 2017 Jan; 8(5):7878-7890. PubMed ID: 28002802
[TBL] [Abstract][Full Text] [Related]
20. LY294002 and metformin cooperatively enhance the inhibition of growth and the induction of apoptosis of ovarian cancer cells.
Li C; Liu VW; Chan DW; Yao KM; Ngan HY
Int J Gynecol Cancer; 2012 Jan; 22(1):15-22. PubMed ID: 22080879
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
